Nexletol Global Market Report 2025

The nexletol market size has grown rapidly in recent years. It will grow from $2.81 billion in 2024 to $3.21 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The historical growth can be attributed to the rising prevalence of hypercholesterolemia, increased awareness of cardiovascular risks, growing demand for alternatives to statins, higher incidence of statin intolerance, and increased adoption of oral lipid-lowering therapies.

The nexletol market size is expected to see rapid growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. Factors driving this growth include a greater focus on preventive healthcare, the increasing prevalence of dyslipidemia, the adoption of digital health technologies, broader global market access, and a rise in clinical approvals and label expansions. Key trends anticipated during the forecast period include advancements in digital health for remote patient monitoring, development of triple combination therapies to enhance LDL-C reduction, innovations in personalized medicine for cholesterol treatment, integration of telemedicine platforms to improve patient access, and progress in clinical trials supporting expanded label indications.

The rising incidence of cardiovascular diseases is expected to drive the growth of the Nexletol market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The surge in these conditions is primarily linked to increasingly sedentary lifestyles, which contribute to weight gain, metabolic imbalances, and elevated blood pressure, thereby heightening the risk of heart-related issues. Nexletol plays a crucial role in managing cardiovascular diseases by lowering low-density lipoprotein (LDL) cholesterol levels, which helps prevent plaque buildup in arteries and reduces the likelihood of heart attacks and other cardiovascular events. For instance, in January 2025, a report published by the American Heart Association, a US-based nonprofit organization, revealed that the United States recorded 941,652 deaths due to cardiovascular disease in 2022, an increase of over 10,000 compared to 931,578 CVD-related deaths in 2021. This upward trend underscores the growing demand for treatments like Nexletol.

Key players in the Nexletol market are increasingly focusing on the development of advanced non-statin therapies as effective alternatives for cholesterol management. Non-statin therapies refer to treatments that lower cholesterol or manage cardiovascular risk without relying on statin medications. For example, in August 2022, Esperion Therapeutics, a US-based pharmaceutical firm, announced that bempedoic acid (NEXLETOL) received recognition from the American College of Cardiology (ACC) as a significant oral non-statin option for reducing LDL-cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD). This endorsement, issued by the ACC's Task Force on Expert Consensus Decision Pathways (ECDP), highlights bempedoic acid’s value, particularly for patients who cannot tolerate statins, reinforcing its expanding role in cardiovascular treatment.

In May 2025, HLS Therapeutics, a pharmaceutical company based in Canada, entered into a partnership with Esperion Therapeutics to commercialize Nexletol. The collaboration is aimed at expanding the accessibility of Nexletol and Nexlizet in Canada, offering additional treatment options for individuals with elevated LDL-C levels, especially those who are intolerant to statins or unable to achieve their LDL-C targets with existing therapies. Esperion Therapeutics, based in the United States, is the developer of NEXLETOL.

Major players in the nexletol market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, Divi’s Laboratories Limited, Esperion Therapeutics Inc., and Neopharm Inc.

North America was the largest region in the nexletol market in 2024. The regions covered in nexletol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nexletol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nexletol is a medication that functions by targeting and inhibiting a specific enzyme involved in cholesterol production in the liver. Its primary use is to reduce low-density lipoprotein cholesterol (LDL-C), often referred to as bad cholesterol, in adults with certain cardiovascular conditions.

The main types of Nexletol include the 180mg dosage and other variations. The 180mg refers to a specific strength of the medication, indicating the amount of active ingredient per dose. It can be administered through oral, injectable, or intravenous routes and is used for treating conditions such as hyperlipidemia, atherosclerosis, and cardiovascular disease. Nexletol is utilized by various end-users, including hospitals, clinics, and homecare settings.

The nexletol market research report is one of a series of new reports that provides nexletol market statistics, including the nexletol industry global market size, regional shares, competitors with the nexletol market share, detailed nexletol market segments, market trends, and opportunities, and any further data you may need to thrive in the nexletol industry. This nexletol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nexletol market consists of sales of non-statin lipid-lowering agents, dietary supplements, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.